The Lutetium Project: Nuclear Medicine and Radiotherapy Personalizing Neuroendocrine Treatment Together

Neuroendocrine Tumors (NETs) are cells that arise from the endocrine and nervous systems. Treatment options for metastatic well differentiated NETs are limited. The lesions can be chemo resistant and external beam radiotherapy can only be used for symptom control. Well differentiated NETs usually have an over expression of somatostatin receptors and this can be used to assess tumor burden and as a treatment modality. This abstract describes the initial experience of a phase-II trial, implemented across four Ontario centers, which aims to administer an individualized dose of radiopharmaceutical Lutetium-177 Dotatate (177Lu) to 150 receptor positive patients with NETs.
Source: Journal of Medical Imaging and Radiation Sciences - Category: Radiology Authors: Source Type: research